Noradrenalin vs Terlipressin in Hepatorenal Syndrome

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Turin, Italy
• Treatments: Lypressin; Norepinephrine; Terlipressin

Criteria

Inclusion Criteria:

• Hepatorenal syndrome

• Age: 18-75 years

• Informed written consent

Exclusion Criteria:

• Multinodular hepatocellular carcinoma (more than 3 nodules)

• Portal vein thrombosis

• Ongoing bacterial infection

• Ongoing or recent (less than one week) bleeding

• Cardio-pulmonary failure

• Coronary artery disease

• Peripheral artery disease

• Arterial hypertension